Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Open Access
- 1 June 2015
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 74 (6) , 1087-1093
Abstract
Background Patients with rheumatoid arthritis (RA) have an increased risk of certain solid cancers, in particular lung cancer, compared to the general population. Treatment with tumour necrosis factor (TNF) inhibitors (TNFi) may further enhance this risk. Objectives To compare the risk of solid cancer in patients with RA treated with TNFi to that in patients treated with non-biologic (synthetic) disease modifying antirheumatic drugs (sDMARDs). Methods Patients with a physician diagnosis of RA enrolled in the British Society for Rheumatology Biologics Register, a national prospective cohort study established in 2001 to monitor the long-term safety of TNFi, were followed via record linkage with the national cancer registries until first solid cancer, death, for 5 years, or until 2011. Rates of solid cancers in 11 767 patients without prior cancer who received TNFi were compared to those in 3249 patients without prior cancer treated with sDMARDs. Results 427 solid cancers were reported in 52 549 patient-years follow-up for the TNFi group (81 (95% CI 74 to 89) per 10 000 patient-years) and 136 cancers were reported in 11 672 patient-years in the sDMARD cohort (117 (95% CI 98 to 138) per 10 000 patient-years). After adjusting for differences in baseline characteristics there was no difference in risk of solid cancer for TNFi compared to sDMARD treated patients: HR 0.83 (95% CI 0.64 to 1.07). There was no difference in the relative risk of cancer for any of the individual TNFi drugs. Conclusions The addition of TNFi to sDMARD does not alter the risk of cancer in RA patients selected for TNFi in the UK.Keywords
This publication has 29 references indexed in Scilit:
- The British Society for Rheumatology Biologics RegisterAnnals of the Rheumatic Diseases, 2005
- Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonistsAnnals of the Rheumatic Diseases, 2005
- Update on the British Society for Rheumatology guidelines for prescribing TNF blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)Rheumatology, 2005
- Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesisNature Medicine, 1999
- Isolated Limb Perfusion with Tumor Necrosis Factor and Melphalan for Limb Salvage in 186 Patients with Locally Advanced Soft Tissue Extremity SarcomasAnnals of Surgery, 1996
- Rheumatoid arthritis and cancer riskEuropean Journal of Cancer, 1996
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- Incidence of Cancer Among Patients With Rheumatoid ArthritisJNCI: Journal of the National Cancer Institute, 1993
- STANFORD HEALTH ASSESSMENT QUESTIONNAIRE MODIFIED TO ASSESS DISABILITY IN BRITISH PATIENTS WITH RHEUMATOID ARTHRITISRheumatology, 1986
- An endotoxin-induced serum factor that causes necrosis of tumors.Proceedings of the National Academy of Sciences, 1975